T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature Medicine

• Publication date

  2007-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm1676PMID 18026115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improving T cell therapy for cancer.

  2007cited by this paper
• Eradication of established tumors in mice by a combination antibody-based therapy

  2007cited by this paper
• Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  2007cited by this paper
• Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.

  2007cited by this paper
• Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo

  2007cited by this paper
• Eradication of established tumors in mice by a combination antibody-based therapy

  2006cited by this paper
• Mechanisms of immune evasion by tumors.

  2006cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• Improving T cell therapy for cancer

  2006cited by this paper
• Centrosome polarization delivers secretory granules to the immunological synapse

  2006cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006cited by this paper
• Overview of Tumor Cell–Based Vaccines

  2006cited by this paper
• Engagement of CD28 Outside of the Immunological Synapse Results in Up-Regulation of IL-2 mRNA Stability but Not IL-2 Transcription1

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Impact of the immunological synapse on T cell signaling.

  2006cited by this paper
• Formulation and delivery issues for monoclonal antibody therapeutics.

  2006cited by this paper
• Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

  2005cited by this paper
• TNF/TNFR family members in costimulation of T cell responses.

  2005cited by this paper
• Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

  2005cited by this paper
• The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.

  2005cited by this paper
• CD80 Cytoplasmic Domain Controls Localization of CD28, CTLA-4, and Protein Kinase Cθ in the Immunological Synapse1

  2005cited by this paper
• Supernatural T cells: genetic modification of T cells for cancer therapy

  2005cited by this paper
• Production of Recombinant Human Trimeric CD137L (4-1BBL)

  2005cited by this paper
• Cross-Linking of 4-1BB Activates TCR-Signaling Pathways in CD8+ T Lymphocytes1

  2005cited by this paper
• Immunosuppressive networks in the tumour environment and their therapeutic relevance

  2005cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• The CD 28 Family : a T Cell Rheostat for Therapeutic Control of T Cell Activation

  2004cited by this paper
• Priming of naive T cells inside tumors leads to eradication of established tumors

  2004cited by this paper
• Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.

  2004cited by this paper
• Genetic modification of T cells for cancer therapy.

  2004cited by this paper
• Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector

  2004cited by this paper
• B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

  2004cited by this paper
• Cytotoxic T lymphocytes form an antigen-independent ring junction.

  2004cited by this paper
• Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele.

  2003cited by this paper
• Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

  2003cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• Targeting tumours with genetically enhanced T lymphocytes

  2003cited by this paper
• Regulation of Lck activity by CD4 and CD28 in the immunological synapse

  2002cited by this paper
• Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

  2002cited by this paper
• When ligand becomes receptor—tolerance via B7 signaling on DCs

  2002cited by this paper
• CD8+ Tumor-Infiltrating T Cells Are Deficient in Perforin-Mediated Cytolytic Activity Due to Defective Microtubule-Organizing Center Mobilization and Lytic Granule Exocytosis

  2001cited by this paper
• The immunological synapse and CD28-CD80 interactions

  2001cited by this paper
• Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells

  2000cited by this paper
• Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.

  1999cited by this paper
• 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.

  1999cited by this paper
• Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.

  1999cited by this paper
• Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway

  1998cited by this paper
• Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.

  1998cited by this paper
• The emerging role of CTLA-4 as an immune attenuator.

  1997cited by this paper
• The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes

  1997cited by this paper
• Activation of CD4+ T cells by delivery of the B7 costimulatory signal on bystander antigen‐presenting cells (trans‐costimulation)

  1994cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper

• Optimally engineered HLA/peptide-specific CAR-T cells outperform TCR-T cells to eradicate solid tumors

  2026cites this paper
• Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

  2026cites this paper
• CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future

  2025cites this paper
• CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity

  2025cites this paper
• Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond

  2025cites this paper
• The tumor necrosis superfamily member 4-1BBL expressed by tumor cells prevents exhaustion of CD8 T cells in a humanized mouse model of papillary renal cell carcinoma

  2025cites this paper
• CAR-T cell therapy: A therapeutic strategy for cancer treatment.

  2025cites this paper
• A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function

  2025cites this paper
• Engineered Immunomodulatory Extracellular Vesicles from Epithelial Cells with the Capacity for Stimulation of Innate and Adaptive Immunity in Cancer and Autoimmunity.

  2025cites this paper
• Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review.

  2025cites this paper
• Challenges in the preclinical design and assessment of CAR-T cells

  2025cites this paper
• CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions

  2025cites this paper
• Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers

  2024cites this paper
• Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors

  2024cites this paper
• CAR-macrophage: Breaking new ground in cellular immunotherapy

  2024cites this paper
• Chimeric Antigen Receptor (CAR)‐T Cells: A New Era for Hepatocellular Carcinoma Treatment

  2024cites this paper
• Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma

  2024cites this paper
• Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies

  2024cites this paper
• PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies

  2024cites this paper
• GD2 targeting CAR T cells for neuroblastoma

  2024cites this paper
• Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma

  2023cites this paper
• An updated overview of the application of CAR‐T cell therapy in neurological diseases

  2023cites this paper
• Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function.

  2023cites this paper
• Recent advances in understanding TCR signaling: a synaptic perspective

  2023influential citation
• Host-cell Interactions of Engineered T cell Micropharmacies

  2023cites this paper
• Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors

  2023cites this paper
• mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

  2023cites this paper
• cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity.

  2023cites this paper
• Chimeric antigen receptor T‐cell therapy in hematologic malignancies: Successes, challenges, and opportunities

  2023cites this paper
• Cis Interactions of Membrane Receptors and Ligands

  2023cites this paper
• CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma

  2023cites this paper
• Host Interactions with Engineered T-cell Micropharmacies

  2023cites this paper
• Leucine zipper-based sorting system enables generation of multi-functional CAR T cells

  2023cites this paper
• TET2 guards against unchecked BATF3-induced CAR T cell expansion

  2023cites this paper
• Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions

  2022cites this paper
• Current updates on generations, approvals, and clinical trials of CAR T-cell therapy

  2022cites this paper
• Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?

  2022cites this paper
• Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.

  2022cites this paper
• The Impact of Different Cell Culture Mediums on CD8+T Cells Expansion: A Bioinformatics Study

  2022cites this paper
• Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?

  2022cites this paper
• HLA-independent T cell receptors for targeting tumors with low antigen density

  2022cites this paper
• CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.

  2022cites this paper
• Terapia de células T con receptores de antígenos quiméricos: revisión de la literatura

  2022cites this paper
• A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination

  2022cites this paper
• Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

  2022cites this paper
• The antigen‐binding moiety in the driver's seat of CARs

  2021cites this paper
• The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy

  2021cites this paper
• 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer

  2021cites this paper
• The potential of CAR T cell therapy for prostate cancer

  2021cites this paper
• CAR-T cells : nouvelle option thérapeutique dans les hémopathies malignes

  2021cites this paper
• Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

  2021cites this paper
• CD8-dependent Tumor Growth Inhibition by Tumor Cells Genetically Modified with 4-1BBL

  2021cites this paper
• Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer

  2021cites this paper
• Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors

  2021influential citation
• Accelerating vein-to-vein cell therapy workflows with new bioanalytical strategies.

  2021cites this paper
• Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology

  2021cites this paper
• Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors

  2021cites this paper
• Strategies for Dodging the Obstacles in CAR T Cell Therapy

  2021cites this paper
• A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells

  2021cites this paper
• Born to survive: how cancer cells resist CAR T cell therapy

  2021cites this paper
• Biomaterials for cancer immunotherapy

  2020cites this paper
• scFv Cloning, Vectors, and CAR-T Production in Laboratory for Preclinical Applications

  2020cites this paper
• New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry

  2020cites this paper
• Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.

  2020cites this paper
• Methods to edit T cells for cancer immunotherapy.

  2020cites this paper
• CAR T cells: continuation in a revolution of immunotherapy.

  2020cites this paper
• Engineering CAR-T Cells for Next-Generation Cancer Therapy.

  2020cites this paper
• A comprehensive review on: Chimeric Antigen Receptor (CAR) T-cell therapy in cancer treatment

  2020cites this paper
• CAR-T cells: Early successes in blood cancer and challenges in solid tumors

  2020cites this paper
• Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction

  2020cites this paper
• Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

  2020cites this paper
• Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery

  2020cites this paper
• The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study

  2020cites this paper
• Potential strategies against resistance to CAR T-cell therapy in haematological malignancies

  2020cites this paper
• A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

  2020cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020cites this paper
• Engineered off-the-shelf therapeutic T cells resist host immune rejection

  2020cites this paper
• New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

  2020cites this paper
• Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

  2020cites this paper
• Engineered off-the-shelf therapeutic T cells resist host immune rejection

  2020cites this paper
• CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress

  2020cites this paper
• T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice

  2020cites this paper
• Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

  2020cites this paper
• PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model

  2020cites this paper
• Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells

  2020cites this paper
• Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.

  2019cites this paper
• Immunodeficiency and Epstein Barr virus induced lymphoproliferation caused by 4-1BB deficiency

  2019cites this paper
• Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule

  2019cites this paper
• Engineering Biomaterial Properties for T Cell Immunotherapy

  2019cites this paper
• Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells

  2019cites this paper
• Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

  2019cites this paper
• Harnessing the Immune System to Target Cancer Cells

  2019cites this paper
• T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.

  2019cites this paper
• Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

  2019cites this paper
• Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics

  2019cites this paper
• T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors

  2019cites this paper
• Switching on the green light for chimeric antigen receptor T‐cell therapy

  2019cites this paper
• Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies

  2019cites this paper
• Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma.

  2019cites this paper
• Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.

  2019cites this paper